Care on Demand Insurance Options | NYU Langone Health
Most major insurance carriers cover the cost of a walk-in primary care visit at NYU Langone’s Care on Demand.
CAreful Ventilation In ARDS The CAVIARDS Trial
A basket trial design examines a single intervention in multiple disease populations . This basket trial consists of an identical 2-arm mechanical ventilation protocol implemented in two different study populations (COVID-19 and non-COVID-19 patients). As per a typical basket trial design, the operational structure of both CAVIARDS-19 and CAVIARDS-non substudies is shared (recruitment, procedures, data collection, analysis, management, etc.). Note that the protocol and all procedures are identical between the two substudies in this basket trial. The only differences between the two studies will be the randomization stratified by suspection of COVID-19, as clarified in Section 4.5.
Caring for the LGBTQ+ Community | NYU Langone Health
NYU Langone provides members of the LGBTQ+ community with healthcare that is respectful of their individual needs.
Carotid Artery Disease | NYU Langone Health
NYU Langone doctors and vascular surgeons are experts in managing carotid artery disease.
Carpal Tunnel Syndrome | NYU Langone Health
NYU Langone physicians and therapists work together to create a customized treatment plan for people with carpal tunnel syndrome.
Cataract | NYU Langone Health
NYU Langone doctors use the latest technology to remove a cataract and restore eyesight safely and successfully.
Catheter Ablation for Atrial Fibrillation & Atrial Flutter | NYU Langone Health
NYU Langone heart rhythm specialists perform catheter ablation to manage and even stop the symptoms of atrial fibrillation and atrial flutter.
Catheter Ablation for Supraventricular Arrhythmias | NYU Langone Health
NYU Langone heart rhythm specialists may perform catheter ablation to manage a supraventricular arrhythmia.
Catheter-Based Treatments for Adult Congenital Heart Disease | NYU Langone Health
NYU Langone experts perform procedures, including cardiac catheterization and catheter ablation, to manage adult congenital heart disease.
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed manifestation of the disease, often causing functional and/or mobility impairment andreduction in health related quality of life. The first experience with alpelisib in overgrowth related to mutation in PIK3CA gene provides the direct evidence of clinical improvement in participants supporting PIK3CA inhibition as a promising therapeutic strategy in participants with PROS. PROS is a serious condition with no approved pharmacological treatment targeting the underlying cause of the disease. Current therapy includes debulking surgery, amputation, and/or endovascular occlusive procedures and mainly addresses symptoms and complications of the disease. There is a high unmet medical need for an effective systemic treatment.The purpose of this study is to assess the efficacy, safety/tolerability and evaluate pharmacokinetics (PK) of alpelisib in participants of different ages with confirmed diagnosis of PROS. As the disease continues throughout the participant life and may be diagnosed at different time points (Keppler-Noreuil et al 2014), the study will enroll adult participants (Group 1; treated with film-coated tablets (FCT)), 6-17 years old pediatric participants (Group 2; treated with FCT), and two exploratory sets of 2-5 years old pediatric participants (Group 3 treated with granules and Group 4 treated with FCT).Group 3 will be enrolled after the completion of the primary analysis when the efficacy, safety and PK data will be available from the participants in Groups 1 and 2 in addition to the data from Group 4 as available, in order to select the recommended dose forparticipants in Group 3. Recruitment of participants in Group 3 will start only after submission and approval of a Substantial Global Protocol Amendment specific to this group. Group 4 will be enrolled before Group 3 and immediately after implementation of this Global Protocol Amendment 01.